<!DOCTYPE html>
<!-- paulirish.com/2008/conditional-stylesheets-vs-css-hacks-answer-neither/
-->
<!--[if lt IE 7]>
<html class="no-js lt-ie9 lt-ie8 lt-ie7" lang="en">
<![endif]-->
<!--[if IE 7]>
<html class="no-js lt-ie9 lt-ie8" lang="en">
<![endif]-->
<!--[if IE 8]>
<html class="no-js lt-ie9" lang="en">
<![endif]-->
<!--[if gt IE 8]>
<!-->
<html class="no-js" lang="en">
<!--<![endif]-->

<head>
    <meta charset="utf-8" />
    <!-- Set the viewport width to device width for mobile -->
    <meta name="viewport" content="width=device-width" />
    <title>
        PracticeUpdate : Expert Opinion Item
    </title>
    <link rel="stylesheet" href="assets/css/app.css">
    <link rel="stylesheet" href="assets/css/font-awesome.css">
    <link rel="stylesheet" href="assets/css/fc-webicons.css">
    <link rel="stylesheet" href="assets/css/foundation-icons-general.css">
    <script src="assets/js/foundation/modernizr.foundation.js">
    </script>
    <!-- IE Fix for HTML5 Tags -->
    <!--[if lt IE 9]>
        <script src="http://html5shiv.googlecode.com/svn/trunk/html5.js">
        </script>
    <![endif]-->
</head>

<body id="page" class="update off-canvas slide-nav expert-opinion-item logged-out">
    <div class="widget ad">
        <div id="leaderboard" class="Breast ad-container">
            <div class="ad-title">
                <span class="ad-title-text">
                    advertisement
                </span>
            </div>
            <!--/.ad-title-->
            <div id="leaderboardcontent" class="ad-content">
            </div>
            <!--.ad-content-->
        </div>
        <!--/#leaderboard.ad-container-->
    </div>
    <!--/.widget.ad-->
    <div class="page-header">
    </div>
    <!--/.page-header-->
    <div class="page-content">
        <section role="main">
            <div class="single-item-container">
                <article class="type-expert-opinion single-item">
                    <!-- info taken from: http://oncologystat.com/viewpoints/seminal_articles/Seminal_Articles_Germ_Cell_Tumors.html
                    -->
                    <div class="item-header-container">
                        <header class="item-header">
                            <div class="flag-container">
                                <span class="flag featured">
                                    <i class="icon-bolt">
                                    </i>
                                    featured
                                </span>
                                <span class="flag story-of-the-week">
                                    <i class="icon-bolt">
                                    </i>
                                    story of the week
                                </span>
                            </div>
                            <div class="meta pub-meta">
                                <span class="item-type">
                                    Seminal Article
                                </span>
                                <span class="item-pub-date">
                                    <time datetime="12-12-19">
                                        December 19, 2012
                                </span>
                            </div>
                            <hgroup class="item-title-container">
                                <h1 class="item-title">
                                    Seminal Articlesâ€”Lymphoma
                                </h1>
                                <p class="item-citation">
                                    <!-- {{source.citation}} -->
                                    2012 Mar 26, Andre Goy, MD, Editor: Patrick Morris, MD
                                </p>
                            </hgroup>
                            <!-- /.item-title-container -->
                        </header>
                    </div>
                    <!--/.item-header-container-->
                    <div class="item-content-container">
                        <div class="item-content">
                            <div class="item-content-section">
                                <section class="seminal-article-body">
                                    <div class="seminal-article-body-container">
                                        <div class="source-container">
                                            <div class="vcard">
                                            </div>
                                            <!--/.vcard-->
                                        </div>
                                        <!--/.source-container-->
                                        <p>Based on our expert&acirc;&euro;&trade;s review, here are the must-read articles for
										  every oncologist about lymphoma.</p>

										  <p><strong>Hodgkin&acirc;&euro;&trade;s Disease</strong></p>

										  <p>1. Aleman BM, Raemaekers JM, Tirelli U, et al. Involved-field radiotherapy for
										  advanced Hodgkin's lymphoma. <a target="_blank" href=
										  "http://www.nejm.org/doi/full/10.1056/NEJMoa022628">N Engl J Med.
										  2003;348(24):2396-2406</a>. <strong>Free</strong></p>

										  <p>2. Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD
										  chemotherapy with a strategy that includes radiation therapy in patients with
										  limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials
										  Group and the Eastern Cooperative Oncology Group. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/23/21/4634.full?sid=cdbeacf5-2d02-40d1-9264-780c5c5eddca">
										  J Clin Oncol. 2005;21:4634-4642</a>. <strong>Free</strong></p>

										  <p>3. Gallamini A, Hutchings M, Rigacci L. Early interim
										  2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior
										  to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a
										  joint Italian-Danish study. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/25/24/3746.full.pdf">J Clin Oncol.
										  2007;25:3746-3752</a>. <strong>Free</strong></p>

										  <p>4. Johnston PB, Inwards DJ, Colgan JP. A Phase II trial of the oral mTOR inhibitor
										  everolimus in relapsed Hodgkin lymphoma. <a target="_blank" href=
										  "http://onlinelibrary.wiley.com/doi/10.1002/ajh.21664/abstract;jsessionid=E1C252C06D02875343EE9652D34B0A2F.d02t02">
										  Am J Hematol. 2010;85(5):320-324</a>.</p>

										  <p>5. Bluhm EC, Ronckers C, Hayashi RJ. Cause-specific mortality and second cancer
										  incidence after non-Hodgkin lymphoma: a report from the Childhood Cancer Survivor
										  Study. <a target="_blank" href=
										  "http://bloodjournal.hematologylibrary.org/content/111/8/4014.full.pdf">Blood.
										  2008;111:4014-4021</a>. <strong>Free</strong></p>

										  <p><strong>Non-Hodgkin&acirc;&euro;&trade;s Lymphoma</strong></p>

											  <p><strong>Follicular and Low Grade Lymphomas</strong></p>

										  <p>6. Rummel MJ, Niederle N, Maschmeyer G, et al. Bendamustine plus R is superior in
										  respect of progression free survival and CR rate when compared to CHOP plus R as
										  first-line treatment of patients with advanced follicular, indolent, and mantle cell
										  lymphomas: final results of a randomized Phase III study of the StiL (Study Group
										  Indolent Lymphomas, Germany). <a target="_blank" href=
										  "http://ash.confex.com/ash/2009/webprogram/Paper20178.html">Presented at: 51st Annual
										  American Society of Hematology Meeting; December 5-8, 2009; New Orleans, LA</a>.</p>

										  <p>7. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in
										  patients with high tumour burden follicular lymphoma responding to rituximab plus
										  chemotherapy (PRIMA): a phase 3, randomised controlled trial. <a target="_blank" href=
										  "http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2810%2962175-7/fulltext#article_upsell">
										  Lancet. 2011 Jan 1;377(9759):42-51. Epub 2010 Dec 20</a>. Elsevier</p>

										  <p>8. van Oers MHJ, Van Glabbeke M, Giurgea L, et al. Rituximab maintenance treatment
										  of relapsed/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC
										  20981 phase III randomized intergroup study. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/early/2010/05/03/JCO.2009.26.5827.full.pdf+html">J
										  Clin Oncol. 2010 Jun 10;28(17):2853-2858</a>. <strong>Free</strong></p>

										  <p>9. Friedberg JW, Taylor MD, Cerhan JR, et al. Follicular Lymphoma in the United
										  States: First Report of the National LymphoCare Study. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/27/8/1202.full">J Clin Oncol. 2009 March
										  2009;27(8):1202-1208</a>.</p>

										  <p>10. Kaminski MS, Tuck M, Estes J, et al. 131I-tositumomab therapy as initial
										  treatment for follicular lymphoma. <a target="_blank" href=
										  "http://www.nejm.org/doi/full/10.1056/NEJMoa041511#t=articleTop">N Engl J Med. 2005 Feb
										  3;352(5):441-449</a>.</p>

										  <p>11. Morschhauser F, Radford J, Van Hoof A, et al. Phase III trial of consolidation
										  therapy with yttrium-90&ndash;ibritumomab tiuxetan compared with no additional therapy
										  after first remission in advanced follicular lymphoma. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/26/32/5156.full">J Clin Oncol. 2008 Nov
										  10;26(32):5156-5164</a>.</p>

										  <p>12. Fowler N, Kahl BS, Rosen P, et al. Bortezomib, bendamustine, and R in patients
										  with relapsed or refractory follicular lymphoma: encouraging activity in the Phase 2
										  VERTICAL study. <a target="_blank" href=
										  "http://ash.confex.com/ash/2009/webprogram/Paper19091.html">Presented at: 51st Annual
										  American Society of Hematology Meeting; December 5-8, 2009; New Orleans, LA</a>.</p>

										  <p>13. Czuczman MS, Weaver R, Alkuzweny B, et al. Prolonged clinical and molecular
										  remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with
										  rituximab plus CHOP chemotherapy: 9-year follow-up. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/22/23/4711.full.pdf">J Clin Oncol. 2004 Dec
										  1;22(23):4711-4716</a>. <strong>Free</strong></p>

										  <p>14. Marcus R, Imrie K, Solal-Celigny P, et al. Phase III study of R-CVP compared
										  with cyclophosphamide, vincristine, and prednisone alone in patients with previously
										  untreated advanced follicular lymphoma. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/26/28/4579.full">J Clin Oncol. 2008 Oct
										  1;26(28):4579-4586</a>. <strong>Free</strong></p>

										  <p>15. Czuczman MS, Koryzna A, Mohr A, et al. Rituximab in combination with fludarabine
										  chemotherapy in low-grade or follicular lymphoma. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/23/4/694.full.pdf">J Clin Oncol. 2005 Feb
										  1;23(4):694-704</a>. <strong>Free</strong></p>

										  <p>16. Robinson KS, Williams ME, van der Jagt RH, et al. Phase II multicenter study of
										  bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell
										  non-Hodgkin's lymphoma. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/26/27/4473.full">J Clin Oncol. 2008 Sep
										  20;26(27):4473-4479. Epub 2008 Jul 1</a>. <strong>Free</strong></p>

											  <p><strong>Diffuse Large B-Cell and High Grade Lymphomas</strong></p>

										  <p>17. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with
										  chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's
										  lymphoma. <a target="_blank" href=
										  "http://www.nejm.org/doi/full/10.1056/NEJM199807023390104">N Engl J Med. 1998 Jul
										  2;339(1):21-26</a>. <strong>Free</strong></p>

										  <p>18. Gutierrez M, Chabner BA, Pearson D, et al. Role of a doxorubicin-containing
										  regimen in relapsed and resistant lymphomas: an 8-year follow-up study of EPOCH.
										  <a target="_blank" href="http://jco.ascopubs.org/content/18/21/3633.full.pdf">J Clin
										  Oncol. 2000 Nov 1;18(21):3633-3642</a>. <strong>Free</strong></p>

										  <p>19. Blayney DW, LeBlanc ML, Grogan T, et al Southwest Oncology Group. Dose-intense
										  chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin,
										  vincristine, and prednisone may improve survival in intermediate- and high-grade
										  lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). <a target=
										  "_blank" href="http://jco.ascopubs.org/content/21/13/2466.full">J Clin Oncol. 2003 Jul
										  1;21(13):2466-2473</a>. <strong>Free</strong></p>

										  <p>20. Kewalramani T, Zelenetz AD, Nimer SD, et al. Rituximab and ICE as second-line
										  therapy before autologous stem cell transplantation for relapsed or primary refractory
										  diffuse large B-cell lymphoma. <a target="_blank" href=
										  "http://bloodjournal.hematologylibrary.org/content/103/10/3684.full.pdf">Blood. 2004
										  May 15;103(10):3684-3688. Epub 2004 Jan 22</a>. <strong>Free</strong></p>

										  <p>21. Pfreundschuh M, Tr&Atilde;&frac14;mper L, Kloess M, et al. Two-weekly or
										  3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly
										  patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL.
										  <a target="_blank" href=
										  "http://bloodjournal.hematologylibrary.org/content/104/3/634.long">Blood. 2004 Aug
										  1;104(3):634-641</a>. <strong>Free</strong></p>

										  <p>22. El Gnaoui T, Dupuis J, Belhadj K, et al. Rituximab, gemcitabine and oxaliplatin:
										  an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma
										  not candidates for high-dose therapy. <a target="_blank" href=
										  "http://annonc.oxfordjournals.org/content/early/2007/05/11/annonc.mdm133.full">Ann
										  Oncol. 2007 Aug;18(8):1363-8136. Epub 2007 May 11</a>.</p>

										  <p>23. Wilson WH, Dunleavy K, Pittaluga S, et al. Phase II study of dose-adjusted EPOCH
										  and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal
										  center and post-germinal center biomarkers. <a target="_blank" href=
										  "http://jco.ascopubs.org/content/26/16/2717.full">J Clin Oncol. 2008 Jun
										  1;26(16):2717-2724. Epub 2008 Mar 31</a>.</p>

										  <p>24. Delarue R, Tilly H, Salles G, et al. R-CHOP14 compared to R-CHOP21 in elderly
										  patients with diffuse large B-cell lymphoma: results of the interim analysis of the
										  LNH03-6B GELA Study [abstract 406]. <a target="_blank" href=
										  "http://ash.confex.com/ash/2009/webprogram/Paper17811.html">Presented at: 51st Annual
										  American Society of Hematology Meeting; December 5-8, 2009; New Orleans, LA</a>.</p>

										  <p>25. Cunningham D, Smith P, Mouncey P, et al. A phase III trial comparing R-CHOP 14
										  and R-CHOP 21 for the treatment of patients with newly diagnosed diffuse large B-cell
										  non-Hodgkin's lymphoma [abstract 8506]. <a target="_blank" href=
										  "http://meeting.ascopubs.org/cgi/content/abstract/27/15S/8506">J Clin Oncol.
										  2009;27(suppl 15)</a>.</p>

										  <p>26. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients
										  in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard
										  CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de
										  l'Adulte. <a target="_blank" href=
										  "http://bloodjournal.hematologylibrary.org/content/116/12/2040.full.pdf">Blood. 2010
										  Sep 23;116(12):2040-2045. Epub 2010 Jun 14</a>. <strong>Free</strong></p>

										  <p>27. Gisselbrecht C, Glass B, Mounier N, et al. Salvage regimens with autologous
										  transplantation for relapsed large B-cell lymphoma in the rituximab era. <a target=
										  "_blank" href=
										  "http://jco.ascopubs.org/content/early/2010/07/26/JCO.2010.28.1618.full.pdf+html">J
										  Clin Oncol. 2010 Sep 20;28(27):4184-4190. Epub 2010 Jul 26</a>.</p>

											  <p><strong>Burkitt Lymphoma</strong></p>

										  <p>28. Lacasce A, Howard O, Lib S, et al. Modified magrath regimens for adults with
										  Burkitt and Burkitt-like lymphomas: preserved efficacy with decreased toxicity.
										  <a target="_blank" href=
										  "http://www.mendeley.com/research/modified-magrath-regimens-adults-burkitt-burkittlike-lymphomas-preserved-efficacy-decreased-toxicity/">
										  Leuk Lymphoma. 2004 Apr;45(4):761-767</a>.</p>

										  <p>29. Dunleavy K, et al. A prospective study of dose-adjusted EPOCH with rituximab in
										  adult patients with newly diagnosed Burkitt lymphoma: A regimen with high efficacy and
										  low toxicity. 10th annual international conference on malignant lymphomas. <a target=
										  "_blank" href=
										  "http://www.annonc.oxfordjournals.org/content/19/suppl_4/iv83.full.pdf">Ann Oncol.
										  2008;19(suppl 1) iv:83-83 (abstr 009)</a>.</p>

											  <p><strong>AIDS-Related Lymphomas</strong></p>

										  <p>30. Wang ES, Straus DJ, Teruya-Feldstein J, et al. Intensive chemotherapy with
										  cyclophosphamide, doxorubicin, high-dose methotrexate/ifosfamide, etoposide, and
										  high-dose cytarabine (CODOX-M/IVAC) for human immunodeficiency virus-associated Burkitt
										  lymphoma. <a target="_blank" href=
										  "http://onlinelibrary.wiley.com/doi/10.1002/cncr.11628/full">Cancer. 2003 Sep
										  15;98(6):1196-1205</a>. <strong>Free</strong></p>

										  <p>31. Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired
										  immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of
										  antiretroviral therapy suspension and tumor biology. <a target="_blank" href=
										  "http://bloodjournal.hematologylibrary.org/content/101/12/4653.full.pdf+html">Blood.
										  2003 Jun 15;101(12):4653-4659. Epub 2003 Feb 27</a>. <strong>Free</strong></p>

											  <p><strong>Extranodal and Cutaneous Lymphomas (including Peripheral T-Cell
											  Lymphoma)</strong></p>

										  <p>32. Swerdlow SH. WHO Classification of Tumours of Haematopoietic and Lymphoid
										  Tissues. 4th ed. Lyon, France: <a target="_blank" href=
										  "http://www.sciencedirect.com/science/article/pii/S000927970900458X">International
										  Agency for Research on Cancer; 2008</a>.</p>

										  <p>33. Armitage J, Vose J, Weisenburger D. International peripheral T-cell and natural
										  killer/T-cell lymphoma study: pathology findings and clinical outcomes. <a target=
										  "_blank" href="http://jco.ascopubs.org/content/26/25/4124.full.pdf+html">J Clin Oncol.
										  2008 Sep 1;26(25):4124-4130. Epub 2008 Jul 14</a>.</p>

										  <p>34. Savage KJ, Harris NL, Vose JM, et al. ALK- anaplastic large-cell lymphoma is
										  clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell
										  lymphoma, not otherwise specified: report from the International Peripheral T-Cell
										  Lymphoma Project. <a target="_blank" href=
										  "http://bloodjournal.hematologylibrary.org/content/111/12/5496.full.pdf+html">Blood.
										  2008 Jun 15;111(12):5496-5504. Epub 2008 Apr 2</a>. <strong>Free</strong></p>

										  <p>35. Au WY, Weisenburger DD, Intragumtornchai T, et al. Clinical differences between
										  nasal and extranasal NK/T-cell lymphoma: a study of 136 cases from the International
										  Peripheral T-cell Lymphoma Project. <a target="_blank" href=
										  "http://bloodjournal.hematologylibrary.org/content/113/17/3931.full.pdf+html">Blood.
										  2008 Nov 24 [Epub ahead of print]</a>. <strong>Free</strong></p>
                                    </div>
                                    <!--/.seminal-article-body-container -->
                                </section>
                                <!-- /.seminal-article-body -->
                            </div>
                            <!-- ./item-content-section -->
                        </div>
                        <!-- ./item-content -->
                    </div>
                    <!-- /.item-conten-container -->
                    <hr />
                    <footer class="copyright item-footer">
                        <img class="logo" src="content/img/feed/imng_logo.gif" alt="IMNG Medical Media"
                        />
                        <p>
                            Copyright &copy; 2012 Elsevier
                        </p>
                    </footer>
            </div>
            <!--/.item-container-->
            <div class="recommended">
                <div class="recent">
                </div>
                <!--/.recent-->
                <div class="ad">
                    <img src="http://placehold.it/300x250" align="ad" title="ad" />
                </div>
            </div>
            <!--/.recommended-->
        </section>
        <!--/[role="main"]-->
        <section id="sidebar" role="complementary">
            <div class="dashboard">
                <div class="panel cta register">
                    <p>
                        <!-- Meet Our Experts -->
                        Become a member to customize this page.
                        <p>
                            <a class="button" href="#action-register">Register for free</a>
                </div>
                <!--/.panel.cta.register-->
                <div class="component user-console">
                </div>
                <!--/.component.user-console-->
                <div class="component user-topic">
                </div>
                <!--/.component.user-topic-->
                <div class="component topic-spotlight">
                </div>
                <!--/.component.topic-spotlight-->
                <div class="panel">
                    <img src="http://placehold.it/200x200" />
                    <p>
                        <!-- Meet Our Experts -->
                        Meet our Advisory and Editorial Boards comprised of physician editors
                        and world-renowned experts.
                        <p>
                </div>
            </div>
            <!--/.sidebar-->
        </section>
        <!--/.[role="complimentary"]-->
    </div>
    <!--/.page-content-->
	<div class="page-footer-container">
    <footer class="page-footer">
    </footer>
	</div><!-- /.page-footer-container -->
    <!-- /.page-footer -->
    <!-- Included JS Files (Uncompressed) -->
    <script src="assets/js/foundation/jquery.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.accordion.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.alerts.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.buttons.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.forms.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.mediaQueryToggle.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.navigation.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.orbit.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.reveal.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tabs.js">
    </script>
    <script src="assets/js/foundation/jquery.foundation.tooltips.js">
    </script>
    <script src="assets/js/foundation/jquery.placeholder.js">
    </script>
    <script src="assets/js/foundation/app.js">
    </script>
    <script src="assets/js/foundation/jquery.offcanvas.js">
    </script>
    <script src="assets/js/mustache.js">
    </script>
    <!-- Mustache - homepage feed template -->
    <script>
                    	<!--
	Mustache - homepage feed template -->
	$.getJSON('content/json/feed.json', function(data) {
	    $.get('assets/mustache/feed-item.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.stream-container').html(html);
	    });

	});

	<!--
	Mustache - homepage recent template -->
	$.getJSON('content/json/recent.json', function(data) {
	    $.get('assets/mustache/recent.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.recent').html(html);
	    });

	});

	<!--
	Mustache - homepage user - console template -->
	$.getJSON('content/json/user-console.json', function(data) {
	    $.get('assets/mustache/user-console.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-console').html(html);
	    });
	});

	<!--
	Mustache - homepage user - topic template -->
	$.getJSON('content/json/user-topic.json', function(data) {
	    $.get('assets/mustache/user-topic.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.user-topic').html(html);
	    });
	});

	<!--
	Mustache - homepage topic - spotlight template -->
	$.getJSON('content/json/topic-spotlight.json', function(data) {
	    $.get('assets/mustache/topic-spotlight.mustache', function(template) {
	        //alert('Load was performed.');
	        var html = Mustache.to_html(template, data);
	        $('.topic-spotlight').html(html);
	    });
	});
</script>
</body>

</html>